AU2022298662B2 - An incretin analog for use in glycemic control and weight management - Google Patents

An incretin analog for use in glycemic control and weight management Download PDF

Info

Publication number
AU2022298662B2
AU2022298662B2 AU2022298662A AU2022298662A AU2022298662B2 AU 2022298662 B2 AU2022298662 B2 AU 2022298662B2 AU 2022298662 A AU2022298662 A AU 2022298662A AU 2022298662 A AU2022298662 A AU 2022298662A AU 2022298662 B2 AU2022298662 B2 AU 2022298662B2
Authority
AU
Australia
Prior art keywords
glycemic control
weight management
incretin analog
incretin
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022298662A
Other languages
English (en)
Other versions
AU2022298662A1 (en
Inventor
Tamer Coskun
Zvonko MILICEVIC
Shweta Urva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2022298662A1 publication Critical patent/AU2022298662A1/en
Application granted granted Critical
Publication of AU2022298662B2 publication Critical patent/AU2022298662B2/en
Priority to AU2025220848A priority Critical patent/AU2025220848A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022298662A 2021-06-23 2022-06-22 An incretin analog for use in glycemic control and weight management Active AU2022298662B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025220848A AU2025220848A1 (en) 2021-06-23 2025-08-22 An incretin analog for use in glycemic control and weight management

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213956P 2021-06-23 2021-06-23
US63/213,956 2021-06-23
PCT/US2022/034437 WO2022271767A1 (en) 2021-06-23 2022-06-22 An incretin analog for use in glycemic control and weight management

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025220848A Division AU2025220848A1 (en) 2021-06-23 2025-08-22 An incretin analog for use in glycemic control and weight management

Publications (2)

Publication Number Publication Date
AU2022298662A1 AU2022298662A1 (en) 2024-01-18
AU2022298662B2 true AU2022298662B2 (en) 2025-06-05

Family

ID=82608370

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022298662A Active AU2022298662B2 (en) 2021-06-23 2022-06-22 An incretin analog for use in glycemic control and weight management
AU2025220848A Pending AU2025220848A1 (en) 2021-06-23 2025-08-22 An incretin analog for use in glycemic control and weight management

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025220848A Pending AU2025220848A1 (en) 2021-06-23 2025-08-22 An incretin analog for use in glycemic control and weight management

Country Status (11)

Country Link
US (3) US12496329B2 (enExample)
EP (1) EP4358994A1 (enExample)
JP (1) JP2024524180A (enExample)
KR (1) KR20240024936A (enExample)
CN (1) CN117915939A (enExample)
AU (2) AU2022298662B2 (enExample)
BR (1) BR112023027321A2 (enExample)
CA (1) CA3223313A1 (enExample)
IL (1) IL309604A (enExample)
MX (3) MX2024000213A (enExample)
WO (1) WO2022271767A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102812908B1 (ko) * 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
CN117320740A (zh) * 2021-02-17 2023-12-29 伊莱利利公司 Gip/glp1双重激动剂治疗方法
WO2026037397A1 (zh) * 2024-08-16 2026-02-19 江苏恒瑞医药股份有限公司 Glp-1类似物的医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019125938A1 (en) * 2017-12-21 2019-06-27 Eli Lilly And Company Incretin analogs and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548275T3 (es) 2010-03-01 2015-10-15 Eli Lilly And Company Dispositivo de inyección automático con mecanismo de retardo que incluye un elemento de empuje de funcionamiento doble
KR102589234B1 (ko) 2017-11-21 2023-10-16 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019125938A1 (en) * 2017-12-21 2019-06-27 Eli Lilly And Company Incretin analogs and uses thereof

Also Published As

Publication number Publication date
JP2024524180A (ja) 2024-07-05
US20260091088A1 (en) 2026-04-02
US20240325498A1 (en) 2024-10-03
EP4358994A1 (en) 2024-05-01
KR20240024936A (ko) 2024-02-26
AU2022298662A1 (en) 2024-01-18
CN117915939A (zh) 2024-04-19
IL309604A (en) 2024-02-01
AU2025220848A1 (en) 2025-09-11
US20260091087A1 (en) 2026-04-02
MX2024000213A (es) 2024-04-16
MX2025012714A (es) 2025-11-03
BR112023027321A2 (pt) 2024-03-12
US12496329B2 (en) 2025-12-16
MX2025012713A (es) 2025-11-03
WO2022271767A1 (en) 2022-12-29
CA3223313A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
AU2022298662B2 (en) An incretin analog for use in glycemic control and weight management
EP4074832A4 (en) METHOD FOR GENERATING A NEW GENE IN AN ORGANISM AND USE THEREOF
EP3754515A4 (en) REFRAGMENTATION PROCESS AND SYSTEM IN A DISTRIBUTED STORAGE SYSTEM
EP4262796A4 (en) MACROCYCLES AND THEIR USE
EP4065061A4 (en) PATIENT SUPPORT DEVICE WITH QUARTZ CELL ASSEMBLIES
EP4034941A4 (en) GLASS WITH FUNCTION OF CONTROL IN SECTIONS AND SYSTEM FOR CONTROL OF GLASS IN SECTIONS
EP4269101A4 (en) LAMINATE AND USE THEREOF
EP4178958A4 (en) MACROCYCLES AND THEIR USE
AU2024246994A1 (en) Methods for reducing exogenous insulin use
EP4010083A4 (en) HANDLING AND USE OF ANTIGEN-SPECIFIC REGULATORY T CELLS
HK40102957A (en) An incretin analog for use in glycemic control and weight management
EP4068492A4 (en) BATTERY AND DEVICE
EP4186024A4 (en) SYSTEMS AND METHODS FOR ASSOCIATION OF SHIPS WITH USER ACCOUNTS
AU2022279173B2 (en) Anti-pd-1 polypeptides and their use
HK40111892A (en) 5-mapb or 6-apb for use in drug-assisted psychotherapy
EP4088712A4 (en) COMPOSITION FOR STIMULATING AND BRINGING CHANGES IN THE SURROUNDINGS OF AGING SKIN CELLS
HK40105949A (en) Alpha-sheet polypeptides and their use
CA3267540A1 (en) CUSTOMIZABLE LID INTENDED FOR USE WITH CONVEYOR AND ASSOCIATED PROCESSES
HK40082494A (en) Polypeptide useful in adoptive cell therapy
HK40067284A (en) Peptidomimetic macrocycles and uses thereof
HK40130575A (zh) 适用於在敏感性皮肤上使用的组合物及其使用方法
CA3281533A1 (en) Systems and methods for in vivo cell replacement
EP4219722A4 (en) EXPRESSION VECTOR FOR USE IN A METHANOTROPH
CA3298022A1 (en) Ascarosides and insecticide combinations and methods for use
HK40094147A (en) Macrocycles and their use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)